Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 15/20 | 0.46 |
| ▸ | MMP13 | P45452 | 15/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | MMP9 | P14780 | 4/20 | 0.43 |
| ▸ | MMP3 | P08254 | 3/20 | 0.43 |
| ▸ | MMP8 | P22894 | 2/20 | 0.43 |
| ▸ | MMP14 | P50281 | 2/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8136644 | 0.82 | KCNH2 (0.35) | MMP1MMP13FFAR1FFAR4BCL2L1 | |
| SCHEMBL25364 | 0.75 | MMP1 (0.52) | MMP1MMP13FFAR1FFAR4BCL2L1 | |
| SCHEMBL7208592 | 0.72 | MMP1 (0.45) | MMP1MMP13FFAR1FFAR4BCL2L1 | |
| SCHEMBL7212961 | 0.72 | MMP1 (0.48) | MMP1MMP13FFAR1FFAR4BCL2L1 | |
| SCHEMBL7212977 | 0.70 | MMP1 (0.47) | MMP1MMP13FFAR1FFAR4BCL2L1 | |
| SCHEMBL6962248 | 0.70 | MMP1 (0.76) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL7208148 | 0.70 | MMP1 (0.52) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL27415619 | 0.70 | MMP1 (0.76) | MMP1MMP13FFAR1FFAR4BCL2L1 | |
| SCHEMBL6954815 | 0.69 | MMP1 (0.57) | MMP1MMP13FFAR1FFAR4BCL2L1 | |
| SCHEMBL7886290 | 0.69 | MMP1 (0.62) | MMP1MMP13FFAR1FFAR4BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0977733-B1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2003-09-03 | — | — | EP | claimed |
| US-20020006920-A1 | Arylsulfonylamino hydroxamic acid derivatives | ROBINSON RALPH PELTON (US) | 2002-01-17 | — | — | US | claimed |
| EP-0977733-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1998033768-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-08-06 | — | — | WO | claimed |
| EP-0977733-B1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020006920-A1 | Arylsulfonylamino hydroxamic acid derivatives | ROBINSON RALPH PELTON (US) | 2002-01-17 | — | — | US | disclosed |
| US-6303636-B1 | FOR THERAPY OF ARTHRITIS, CANCER, TISSUE ULCERATION, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCIERITIS, SEPSIS, SEPTIC SHOCK AND OTHER DISEASES INVOLVING THE PRODUCTION OF TUMOR NECROSIS FACTOR | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006920-A1 | Arylsulfonylamino hydroxamic acid derivatives | MMP8, MMP1, MMP10 | MMP1 2/4885MMP13 18/4885FFAR1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.